<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01620554</url>
  </required_header>
  <id_info>
    <org_study_id>P09-16 / BF2.649</org_study_id>
    <secondary_id>2010-019413-25</secondary_id>
    <nct_id>NCT01620554</nct_id>
  </id_info>
  <brief_title>Dose-range Finding Study of BF2.649 Effect on Patients With Obstructive Sleep Apnea (OSA)</brief_title>
  <official_title>Minimum Effective Dose-Finding Study of BF2.649, in Patients With Moderate to Severe OSA, Experiencing EDS Despite Regular Use of nCPAP, and Patients Having Refused This Therapy - Randomized, Double Blind Study With BF2.649 or Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioprojet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioprojet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multicenter, double-blind, phase II, randomized, dose-response study in 5
      parallel groups (dose-range).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obstructive sleep apnea (OSA) is a relatively common condition and is estimated to affect 2
      to 4% of middle-aged adults

      The study medication BF2.649 tested here is a novel, highly potent, selective, orally active
      inverse agonist at the histamine H3 receptor, therefore strengthens histaminergic
      transmission in the brain and increases wakefulness EDS is characterized by daytime
      somnolence and sudden sleep episodes. This problem has several consequences, e.g., an
      impairment of quality of life, an interference with activities of daily living and other
      handicaps in the management of social and family affairs.

      The primary endpoint of this study will be measured by the change in the well-validated
      Epworth sleepiness scale (ESS). The ESS is a simple self-administered 8-item questionnaire.
      The outcome is to get an impression about the level of the daytime sleepiness in several
      real-life situations.

      In this study, each patient will be treated during 2 weeks, and randomly assigned to one the
      5 arms (BF2.649 at one of the 4 possible dosages or placebo).

      The patient will then attend a end-of-treatment visit, in order to assess the particularly
      the ESS score.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Epworth Sleepiness Scale scores (ESS)</measure>
    <time_frame>change of ESS at 2 weeks</time_frame>
    <description>ESS value compared from baseline (Day 0) and End of treatment period (Day 14)</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Obstructive Sleep Apnoea</condition>
  <condition>Excessive Daytime Sleepiness</condition>
  <arm_group>
    <arm_group_label>BF2.649 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BF2.649 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BF2.649 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BF2.649 40mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BF2.649</intervention_name>
    <description>1 capsule per week during 2 weeks</description>
    <arm_group_label>BF2.649 5mg</arm_group_label>
    <other_name>Pitolisant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BF2.649</intervention_name>
    <description>1 capsule per week during 2 weeks</description>
    <arm_group_label>BF2.649 10mg</arm_group_label>
    <other_name>Pitolisant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BF2.649</intervention_name>
    <description>1 capsule per week during 2 weeks</description>
    <arm_group_label>BF2.649 20mg</arm_group_label>
    <other_name>Pitolisant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BF2.649</intervention_name>
    <description>1 capsule per week during 2 weeks</description>
    <arm_group_label>BF2.649 40mg</arm_group_label>
    <other_name>Pitolisant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 capsule per week during 2 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main inclusion Criteria:

          -  Patient with OSA (treated or not with nCPAP) and still complaining of EDS

          -  Epworth Sleepiness Scale score &gt; or = to 11

        Main exclusion Criteria:

          -  Patient suffering from chronic severe insomnia in accordance with the International
             Classification of Sleep Disorders, but without OSA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evelyne De Paillette, MD</last_name>
    <role>Study Director</role>
    <affiliation>Bioprojet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2012</study_first_submitted>
  <study_first_submitted_qc>June 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2012</study_first_posted>
  <last_update_submitted>June 13, 2012</last_update_submitted>
  <last_update_submitted_qc>June 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sleep disorder</keyword>
  <keyword>Obstructive Sleep Apnoea</keyword>
  <keyword>Excessive Daytime Sleepiness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

